Musculoskeletal MRI Fellowship

Sep 6th, 2020Sep 10th, 2020
Barcelona, 56
ES
https://academy.telemedicineclinic.com/fellowships/2992/musculoskeletal-mri-fellowship-sep-2020/
The purpose of this fellowship is to learn about different MSK topics by immersing yourself in a learning environment during five consecutive days.
Latest in Home
Endovascular splenorenal shunt in chronic portal vein thrombosis presented by Dr. Carolin Sobotta University Medicine Goettingen Goettingen, Germany
CIRSE’s ‘Amazing Interventions’ go beyond conventional routes
September 9, 2026
Eshnr 26 Promo Ppt Reg Now 1920x1080 V1 Red
ESHNR heads to Budapest with dental imaging, cancer updates and AI on the agenda
September 9, 2026
20260905 081521 Art6424 Scaled
CIRSE: Patient selection drives local treatment of lung tumours
September 8, 2026
Ck
Video: Charles Kahn on keeping pace with radiology AI
September 7, 2026
More in Home
CIRSE’s ‘Amazing Interventions’ go beyond conventional routes
By Claudia Tschabuschnig
From creating new biliary pathways to targeting elusive lymphatic leaks, specialists at CIRSE 2026 shared inventive interventions for patients with few remaining options.
September 9, 2026
Endovascular splenorenal shunt in chronic portal vein thrombosis presented by Dr. Carolin Sobotta University Medicine Goettingen Goettingen, Germany
ESHNR heads to Budapest with dental imaging, cancer updates and AI on the agenda
By Claudia Tschabuschnig
From dental MRI to imaging after cancer treatment, ESHNR 2026 brings practical challenges and emerging techniques to Budapest on September 10–12. Here’s what to watch for.
September 9, 2026
Eshnr 26 Promo Ppt Reg Now 1920x1080 V1 Red
CIRSE: Patient selection drives local treatment of lung tumours
By Claudia Tschabuschnig
Billed as a controversy session, a discussion of local treatments for lung tumors at CIRSE 2026 highlighted common ground: patient selection, lung preservation, and the complementary roles of radiotherapy and ablation.
September 8, 2026
20260905 081521 Art6424 Scaled
Video: Charles Kahn on keeping pace with radiology AI
By Claudia Tschabuschnig
Dr. Charles Kahn looks beyond the AI hype to examine scientific rigor, better publishing, and what comes next.
September 7, 2026
Ck
Attack severely damages diagnostic imaging center in Odesa
By Claudia Tschabuschnig
After its facility was hit on 2 September, Innova Diagnostica is assessing whether its MRI scanner can be saved and working to restore specialized imaging services.
September 4, 2026
The exterior of Innova Diagnostica shows shattered windows, exposed wiring, damaged air-conditioning units, and debris surrounding the building. Several ground-floor windows have been boarded up. A message painted on the facade reads, “They destroy the future. We help bring it to life.”
MRI-based model shows changes over time in multiple myeloma patients
By Amerigo Allegretto
Whole-body MRI could serve as a scalable biomarker for risk stratification in multiple myeloma patients.
September 4, 2026
Multiple Myeloma 400
What should we teach radiology residents now that the algorithm reads too?
By Dr. Filippo Pesapane
In a new column, Dr. Filippo Pesapane of the European Institute of Oncology (IEO) IRCCS in Italy reflects on the important lessons learned about breast imaging AI technology and how they should impact radiologist training.
September 4, 2026
Filippo Pesapane
MRI shows how hormones affect mood
By Amerigo Allegretto
MRI scans show how higher progesterone levels indicate lower mood.
September 2, 2026
Woman Mother Stressed 400
What to watch for at CIRSE 2026
By Claudia Tschabuschnig
The program spans new treatments, clinical practice, training, and access to IR across Europe.
September 2, 2026
Cirse2025
Q&A with Ken Herrmann: Theranostics must move earlier and beyond established targets
By Claudia Tschabuschnig
Prof. Ken Herrmann discusses the expansion of radioligand therapy into earlier treatment lines, the need for new cancer targets, long-term safety, and the challenge of translating innovation into robust clinical evidence.
September 1, 2026
Prof. Ken Herrmann, director of the Department of Nuclear Medicine at University Hospital Essen, pictured fourth from the left, at the opening opening of a new nuclear medicine center in Essen, Germany, focused on theranostics and personalized cancer care.
AI cuts chest CT reporting time
By Will Morton
Exploratory modeling suggested an approximate reduction of 0.5 full-time equivalent radiologist workload.
September 1, 2026
Example of AI-assisted pulmonary nodule detection and longitudinal volumetric assessment in a 65-year-old woman with peripheral arterial disease, a 24-pack-year smoking history, emphysema, and a family history of lung cancer. An incidental 8.5-mm right lower lobe pulmonary nodule is identified at CT angiography of the abdomen in July 2022 but does not receive follow-up. Subsequent imaging demonstrates interval growth, and CT-guided biopsy confirms stage IA lung adenocarcinoma. Contrast-enhanced axial chest CT images obtained on February 2, 2024, before robotic-assisted thoracoscopic segmentectomy, show a 12.1-mm spiculated right lower lobe pulmonary nodule. (A) Conventional contrast-enhanced axial chest CT image without AI assistance shows a 12.1-mm spiculated right lower lobe pulmonary nodule. (B) Corresponding CT image with AI-assisted pulmonary nodule detection, automated segmentation, and quantitative nodule assessment identifies a solid pulmonary nodule (nodule #1) measuring 13 × 8 (11) mm, with a volume of 739 mm3, a 45% volumetric increase compared with the previous contrast-enhanced chest CT performed on October 9, 2023 (510 mm3), and an estimated volume doubling time (VDT) of 216 days. (C) AI-generated longitudinal nodule analysis displays automated segmentation of the current (February 2, 2024) and previous (October 9, 2023) CT examinations, 3D nodule reconstruction, and quantitative volumetric assessment for longitudinal follow-up. The AI interface is displayed in the original software language (Dutch).
Bayer's PET agent meets endpoints in phase III cardiac amyloidosis study
By Will Morton
Overall sensitivity was 94% (95% CI, 85% to 98%) and specificity was 86% (95% CI, 77% to 92%).
August 31, 2026
This figure shows fused I-124 evuzamitide positron emission tomography (PET)/computed tomography (CT) images from patients without amyloidosis and from patients with ATTR cardiac amyloidosis, early ATTR cardiac amyloidosis, light chain cardiac amyloidosis, gelsolin-mediated amyloidosis, and systemic organ amyloid. The columns represent radiological transaxial, sagittal, and coronal views except for the last row middle and far right columns, which are coronal projections. The blue asterisks represent physiological activity (tracer activity in the stomach and esophagus). The arrowheads represent pathological uptake. Note the small amount of cardiac uptake in the basal septum and the basal lateral walls (likely early ATTR cardiac amyloidosis), splenic uptake and pleural uptake in light chain amyloidosis, and cardiac and kidney uptake in gelsolin-mediated amyloidosis. The bright yellow color represents more tracer uptake.
Page 1 of 92
Next Page